While the curves suggest a potential survival advantage with carboplatin addition, the differences did not reach statistical significance, consistent with our numerical findings.
← all excerpts
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.
1
—
—